---
title: "羅氏的 III 期 Evera 數據表明，Giredestrant 顯著提高了 ER 陽性晚期乳腺癌患者的無進展生存期"
description: "羅氏控股公司：羅氏第三階段 EVERA 數據表明，Giredestrant 顯著改善了雌激素受體陽性晚期乳腺癌患者的無進展生存期"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/261722565.md"
published_at: "2025-10-18T08:58:44.000Z"
---

# 羅氏的 III 期 Evera 數據表明，Giredestrant 顯著提高了 ER 陽性晚期乳腺癌患者的無進展生存期

> 羅氏控股公司：羅氏第三階段 EVERA 數據表明，Giredestrant 顯著改善了雌激素受體陽性晚期乳腺癌患者的無進展生存期

羅氏控股公司：

-   羅氏第三階段 EVERA 數據表明，Giredestrant 顯著改善了雌激素受體陽性晚期乳腺癌患者的無進展生存期

### Related Stocks

- [RHHBY.US - 羅氏(ADR)](https://longbridge.com/zh-HK/quote/RHHBY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Fitch Maintains Ratings of Hikma, Roche Following Corporate Rating Criteria Updates | Fitch Maintains Ratings of Hikma, Roche Following Corporate Rating Criteria Updates | [Link](https://longbridge.com/zh-HK/news/275874477.md) |
| Roche Appoints Mark Dawson As New Head Of Roche Pharma Research And Early Development | Roche Holding AG :ROCHE HOLDING AG - APPOINTMENT OF MARK DAWSON, M.D., PH.D., AS NEW HEAD OF ROCHE PHARMA RESEARCH AND E | [Link](https://longbridge.com/zh-HK/news/276097246.md) |
| Roche's Gazyva Meets Main Goal in Late-stage Kidney Disease Study | Roche's Gazyva Meets Main Goal in Late-stage Kidney Disease Study | [Link](https://longbridge.com/zh-HK/news/276037536.md) |
| Genentech Reports Positive Phase III Results For Gazyva In Primary Membranous Nephropathy | Genentech, part of the Roche Group, announced positive Phase III results for Gazyva in treating primary membranous nephr | [Link](https://longbridge.com/zh-HK/news/276037337.md) |
| Roche Says Its Blood Cancer Drug Shows Positive Results in Trial | Roche announced that its blood cancer drug Gazyva/Gazyvaro has shown positive results in a late-stage trial for patients | [Link](https://longbridge.com/zh-HK/news/276037735.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。